DAISY- Diagnostic AI System for Robotic and Automated Triage and Assessment
NCT06571838
Recruiting
This study aims to introduce an automated triaging system called DAISY into the Emergency Department (ED) to give patients the opportunity to self-direct their initial consultation. This is a new system in development, with a robot like the image at the top of this sheet, a touchscreen that will ask patients a number of questions about their current health (as a Triage nurse or doctor in the Emergency Department may do) but also with some attached devices (like a blood pressure monitor and therm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: York & Scarborough Teaching Hospitals NHS Foundation Trust, York, N. Yorks
Conditions: Emergencies
Register for Updates
CONVERGE Post-Approval Study (PAS)
NCT05393180
Recruiting
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/02/2025
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +24 locations
Conditions: Chronic Atrial Fibrillation
Register for Updates
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390
Recruiting
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Stanford University School of Medicine, Endocrinology, 800 Welch Road,, Palo Alto, California +30 locations
Conditions: Post-Bariatric Hypoglycemia
Register for Updates
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183
Recruiting
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose (MTD) which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose (MAD) will be investigated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: START Midwest, Grand Rapids, Michigan +13 locations
Conditions: Advanced Malignant Solid Tumor
Register for Updates
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT06823713
Recruiting
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/02/2025
Locations: Hospital Universitario Reina Sofía, Córdoba, Not set +11 locations
Conditions: End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases, Fibrosis and Cirrhosis of Liver, Decompensated Liver Cirrhosis, Decompensated Cirrhosis, Steatotic Liver Disease
Register for Updates
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754
Recruiting
A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA). All patients who meet inclusion criteria will be enrolled to receive ivosidenib tablets orally once daily for 28 day cycles, continuing as long as clinical benefit and consent for participation is maintained. There will be a minimum of 6 study visits from screening until the final follow-up, if one cycle of tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Erebouni MC, Yerevan, Not set +77 locations
Conditions: Cholangiocarcinoma
Register for Updates
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
NCT07014735
Recruiting
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance. Drugs like moxifloxacin can further exacerbate this effect, especially in those with diabetes. A previous trial on Type 1 diabetes suggested that hyperglycaemia and moxifloxacin have additive effects, prompting an investigation into whether similar effects occur in Type 2 diabetes (T2D... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/02/2025
Locations: Richmond Pharmacology Ltd., London, Not set
Conditions: Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in, Torsades de Pointes
Register for Updates
Characterising the Neuromuscular Function of Post Stroke Patients
NCT07013188
Recruiting
Strokes are a leading cause of death and disability in developed countries, with significant economic and social impacts. Defined by the WHO, strokes cause rapid and lasting disturbances in cerebral function. In the UK, strokes occur every five minutes, affecting 100,000 people annually and resulting in substantial physical impairments and financial costs. Although stroke-related deaths have decreased due to improved treatments and awareness, strokes remain a major cause of death and disability... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/01/2025
Locations: Royal Derby Hospital branch, School of Medicine, University of Nottingham, Derby, Derbyshire
Conditions: Stroke (CVA) or TIA
Register for Updates
Trial-Ready Cohort-Down Syndrome (TRC-DS)
NCT04165109
Recruiting
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 450 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outc... Read More
Gender:
ALL
Ages:
Between 25 years and 55 years
Trial Updated:
05/30/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +19 locations
Conditions: Down Syndrome, Alzheimer Disease, Dementia
Register for Updates
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Montgomery, Alabama +51 locations
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
The Value of Advanced Imaging Sequences for Fetal MRI in Clinical Practice
NCT03302663
Recruiting
This project is split into 4 sections: 1. Can improvements be made in the Magnetic resonance imaging sequences used to image the fetus in order to improve diagnostic accuracy? 2. Does 3T improve the quality and diagnostic value of fetal MRI when compared to 1.5T 3. Can fetal MRI be used to image the fetal heart? 4. Can fetal MRI be used to image the fetal Bones?
Gender:
FEMALE
Ages:
All
Trial Updated:
05/30/2025
Locations: Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, South Yorkshire
Conditions: Fetal Conditions
Register for Updates
Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias
NCT06661278
Recruiting
The goal of this observational study is to evaluate exercise testing and daily physical activity in children and adolescents who are diagnosed with an inherited arrhythmia. The main question it aims to answer is: Does maximum heart rate during controlled exercise tolerance testing accurately reflect maximum heart rate and peak exercise levels during free living daily physical activity in children and adolescents diagnosed with an inherited arrhythmia? Participants will: * Complete routine exe... Read More
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
05/30/2025
Locations: Royal Brompton Hospital, London Borough of Sutton, Not set +1 locations
Conditions: Long QT Syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia Type 1, Catecholaminergic Polymorphic Ventricular Tachycardia Type 2
Register for Updates